Pharmacoeconomics of mild cognitive impairment.

Full Abstract

There is little written about the pharmacoeconomics of mild cognitive impairment (MCI), particularly with regard to intervention. The aim of the paper is to highlight methodological issues and to present some results that are of importance when drug interventions of MCI are discussed. There is a relationship between severity of dementia and costs, but to what extent such results can be extrapolated to MCI is not known. Even if it is logical to consider a postponement of the shift from MCI to dementia as cost effective, this statement must be proven, particularly in light of the insufficient knowledge about the effects of anti-dementia drugs on survival. From the Kungsholmen project in Sweden, there are indications that the postponement between MCI and manifest dementia may result in short-term benefits (a few years) of about SEK50,000 (5300 US dollars).

Learn Faster Today Improve your study skills

Author information

Author/s: Wimo, Anders (A); Winblad, Bengt (B);

Affiliation: Division of Geriatric Medicine, Neurotec, Karolinska Institutet, Stockholm, Sweden.

Journal and publication information

Publication Type: Journal Article; Review

Journal: Acta neurologica Scandinavica. Supplementum (Acta Neurol Scand Suppl), published in Denmark. (Language: eng)

Reference: 2003-; vol 179 (issue ) : pp 94-9

Dates: Created 2003/02/26; Completed 2003/05/23; Revised 2007/07/23;

PMID: 12603255, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Canada
Cognition Disorders - drug therapy; economics; epidemiology
Comorbidity
Cost of Illness
Cost-Benefit Analysis
Dementia - diagnosis; epidemiology; prevention & control
Drug Costs

These are the highest related articles currently in the database:

See 100+ related articles.